143 related articles for article (PubMed ID: 1607922)
1. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
Robert J; Armand JP; Huet S; Klink-Alakl M; Recondo G; Hurteloup P
J Clin Oncol; 1992 Jul; 10(7):1183-90. PubMed ID: 1607922
[TBL] [Abstract][Full Text] [Related]
2. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.
Mross K; Mayer U; Hamm K; Burk K; Hossfeld DK
Eur J Clin Pharmacol; 1990; 39(5):507-13. PubMed ID: 2076745
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.
Robert J; David M; Huet S; Chauvergne J
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1289-94. PubMed ID: 3181250
[TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
Robert J; Monnier A; Poutignat N; Hérait P
Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia.
Kreis W; Rottach C; Budman DR; Chan K; Schulman P; Allen SL; Weiselberg L; Vinciguerra V
Cancer Res; 1988 Oct; 48(19):5580-4. PubMed ID: 3166400
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J
Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
[TBL] [Abstract][Full Text] [Related]
12. Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).
Dodion P; Davis TA; Rozencweig M; Crespeigne N; Kenis Y; Bachur NR
Invest New Drugs; 1985; 3(4):361-8. PubMed ID: 4086243
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.
Jacquet JM; Bressolle F; Galtier M; Bourrier M; Donadio D; Jourdan J; Rossi JF
Cancer Chemother Pharmacol; 1990; 27(3):219-25. PubMed ID: 2265458
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
Hochster H; Liebes L; Wadler S; Oratz R; Wernz JC; Meyers M; Green M; Blum RH; Speyer JL
J Natl Cancer Inst; 1992 Nov; 84(22):1725-30. PubMed ID: 1433357
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
Miller AA; Schmidt CG
Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
[TBL] [Abstract][Full Text] [Related]
18. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.
Rahman A; Treat J; Roh JK; Potkul LA; Alvord WG; Forst D; Woolley PV
J Clin Oncol; 1990 Jun; 8(6):1093-100. PubMed ID: 2348224
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.
Piscitelli SC; Rodvold KA; Rushing DA; Tewksbury DA
Clin Pharmacol Ther; 1993 May; 53(5):555-61. PubMed ID: 8387903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
